Annette Hasenburg Prof., Dr, med
Director, Obstetrics and Gynecology, Mainz University Medical Center, Mainz, GermanyBiographical Sketch:
Dr. Annette Hasenburg is the Director of Obstetrics and Gynecology at Mainz University Medical Center in Mainz, Germany. She is Head of the ESGO (European Society of Gynaecologic Oncology) Task Force Psycho-Oncology, and is on the board of directors of the Institute of Sexuality and Health of the University Freiburg in Freiburg, Germany.
Dr. Hasenburg received her medical degree from Ruhr-University, Bochum, Germany, where she also received residency training in internal medicine (Evangelisches Krankenhaus Herne) and obstetrics and gynecology (Marienhospital Herne). She received specialist training and qualification in psychotherapy at the Institute of Psychotherapy and Psychosomatic Medicine in Düsseldorf. She completed a postdoctoral fellowship in the Department of Obstetrics and Gynecology, Oncology Division, at Baylor College of Medicine in Houston, Texas.
Until joining the Mainz University Medical Center early in 2016, Dr. Hasenburg was Vice Chairman of the Department of Gynecology and Obstetrics and Associate Professor at the University of Freiburg School of Medicine.
Since 2018, Dr. Hasenburg has been on the Board of Directors of the AGO (Arbeitsgemeinschaft Gynäkologische Onkologie) and since 2020 on the Board of Directors of the DGGG (Deutsche Gesellschaft Gynäkologie und Geburtshilfe).
Positions:
Director, Obstetrics and Gynecology, Mainz University Medical Center, Mainz, Germany; Head, ESGO (European Society of Gynaecologic Oncology) Task Force Psycho-Oncology
Degrees:
Prof. Dr. med: Ruhr-University Bochum, Germany
Postgraduate Training:
Postdoctoral fellowship: obstetrics and gynecology, Oncology Division, Baylor College of Medicine, Houston, Texas
Qualification in Psychotherapy, Institute of Psychotherapy and Psychosomatic Medicine, Düsseldorf, Germany
Disclosures
Dr. Annette Hasenburg received honoraria from: AstraZeneca, Celgen, GSK, LEO Pharma, MedConcept GmbH, Med update GmbH, Medicultus, Pfizer, Promedicis GmbH, Softconsult, Roche Pharma AG, Streamedup!GmbH, Tesaro Bio Germany GmbH
She is in an advisory role for: AstraZeneca, GSK, LEO Pharma, PharmaMar, Promedicis GmbH, Roche Pharma AG, Tesaro Bio Germany GmbH, MSD Sharp&Dohme GmbH
Recent Contributions to PracticeUpdate:
- Pembrolizumab With Chemoradiotherapy Followed by Pembrolizumab for Newly Diagnosed, High-Risk, Locally Advanced Cervical Cancer
- Simple vs Radical Hysterectomy in Women With Low-Risk Cervical Cancer
- Neoadjuvant Chemotherapy Plus Camrelizumab for Locally Advanced Cervical Cancer
- Atezolizumab Plus Bevacizumab and Chemotherapy for Metastatic, Persistent, or Recurrent Cervical Cancer
- ESMO 2023: Recommendations From Dr. Annette Hasenburg for Gynecological Cancer
- ASCO 2023: Abstract Recommendations From Prof. Dr. Annette Hasenburg for Gynecologic Oncology
- 2022 Top Story in Oncology: Results From the Phase II KEYNOTE-158 Study
- Apatinib Plus Pegylated Liposomal Doxorubicin vs Pegylated Liposomal Doxorubicin Alone for Platinum-Resistant Recurrent Ovarian Cancer
- ASCO 2022: Abstract Recommendations From Prof. Dr. Annette Hasenburg for Gynecologic Oncology
- Pembrolizumab in Patients With Microsatellite Instability–High Advanced Endometrial Cancer